Objectives: We discussed which method between the test-negative design (TND) and the screening method (SM) could provide more robust real-time and end-of-season vaccine effectiveness (VE) estimates using data collected from routine influenza surveillance in primary care. Methods: We used data collected during two influenza seasons, 2014e15 and 2015e16. Using the SM, we estimated end-of-season VE in preventing medically attended influenza-like illness and laboratoryconfirmed influenza among the population at risk. Using the TND, we estimated end-of-season VE in preventing influenza among both the general and the at-risk population. We estimated real-time VE using both methods. Results: For the SM, the overall adjusted end-of-season VE was 24% (95% confidence interval (CI), 16 to 32) and 12% (95% CI, À16 to 33) during season 2014e15, and 53% (95% CI, 44 to 60) and 47% (95% CI, 23 to 64) during season 2015e16, in preventing influenza-like illness and laboratory-confirmed influenza, respectively. For the TND, the overall adjusted end-of-season VE was À17% (95% CI, À79 to 24) and À38% (95% CI, À199 to 13) in 2014e15, and 10% (95% CI, À31 to 39) and 18% (95% CI, À33 to 50) in 2015e16, among the general and at-risk population, respectively. Real-time VE estimates obtained through the TND showed more variability across each season and lower precision than those estimated with the SM. Conclusions: Although the worldwide use of the TND allows for comparison of overall VE estimates among countries, the SM performs better in providing robust real-time VE estimates among the population at risk. A.M. Vilcu, Clin Microbiol Infect 2018;24:431.e5e431.e12
Introduction
The main objective of influenza vaccination in France is to prevent complicated influenza infections, hospitalization and mortality in individuals at increased risk for severe influenza disease or complications [1, 2] . Knowledge of influenza vaccine effectiveness (VE) is essential to measure the protective effect of vaccination and to evaluate its public health value, especially among these at-risk groups [3] .
The study design approach used most often to estimate influenza VE is the test-negative design (TND) [4] , which compares the odds of vaccination among influenza testepositive versus influenza testenegative patients, after adjusting for potential confounding factors. This approach has been validated theoretically and is believed to be valid under a range of scenarios [4, 5] .
Another approach used to estimate VE is the screening method (SM), which compares the vaccination coverage between reported cases and a reference group (e.g. the general population from which the reported cases have emerged) [6, 7] . This simple method was designed to be used as a rapid preliminary analysis when incidence and attack rate data are not yet available [8] . This approach is convenient because of its inexpensiveness and reliance on already available data [7,9e11] , but it does not take into account all confounding factors, which may result in biased estimates [7] . Compared to the TND, the SM could be better suited to providing a real-time indication of VE in the field [7,9e12] .
In a related study, important trade-offs in reliability of the SM-VE estimates related to the incompleteness of data collected through the Canadian Public Health Information System have been reported [13] . However, these estimates were obtained from data collected by two distinct surveillance systems (passive and active surveillance data for SM and TND, respectively) and using two diagnostic methods (PCR for SM and culture for TND), which could lead to variations in observed SM and TND-VE estimates [13] .
We thus estimated real-time and final influenza VE with the TND and the SM approach from, firstly, influenza-like illness (ILI) cases reported by the French practice-based surveillance system and laboratory-confirmed influenza cases; and, secondly, two influenza epidemics (2014e15 and 2015e16) with a different epidemiologic and virologic profile (http://invs.santepubliquefrance.fr/beh/2016/ 32-33/2016_32-33_1.html) [14] . The main objective was to establish which method was the most appropriate to estimate influenza VE from data reported by the French influenza surveillance system in primary care.
Methods

Data collected by Sentinelles Network, France
The sentinel general practitioners (SGPs) of the Sentinelles Network [15] report and describe on a weekly basis ILI cases observed among their patients using the following definition: sudden onset of fever (>39 C (>102 F)) with myalgia and respiratory signs [16] .
The sentinel physicians (SGPs and paediatricians) also collect nasopharyngeal samples by swabbing a randomized sample of their patients consulting for ILI. The random sample consisted of the first two ILI patients of the week aged 6 months and older consulting within less than 48 hours since symptom onset and consenting to provide a nasopharyngeal specimen. At the moment of swabbing, epidemiologic data were collected through a standardized paper questionnaire. Periods of specimen collection are illustrated in Supplementary Fig. A1 .
Virologic results were reported by the French National Influenza Reference Center (CNR, Paris and Lyon) and the virology laboratory at the University of Corsica, France. All the laboratories performed real-time reverse-transcriptase PCR tests for virus detection, (sub) typing and determination of the influenza B virus lineage (http:// www.who.int/influenza/gisrs_laboratory/molecular_diagnosis/en/) [17] .
Study population
We estimated VE in two main populations: the general population and the at-risk population.
The general population concerned all individuals aged !6 months who are likely to consult in primary care in case of ILI episodes. Within this general population, an individual was considered at risk if he or she was aged !65 years or presented one of the following risk factors for influenza complications: pregnancy (at any trimester), obesity (body mass index !40 kg/m 2 ) or chronic disease (cardiovascular disease, respiratory disease, immunodeficiency or diabetes) [2] .
Estimation of seasonal VE using SM
The SM's principle is to calculate VE using the following equation [6, 18, 19] :
where PV is the proportion of vaccinated among the population of reference and PVC is the proportion of vaccinated among observed cases. PV was obtained from robust administrative sources (Caisse Nationale d'Assurance Maladie des Travailleurs Salaries (CNAMTS), the main national health insurance system, covering about 85% of the French population) and was available only for the following two at-risk groups: aged <65 years with chronic disease, and aged !65 years [2, 9, 20] . Therefore, VE could be estimated only in these at-risk groups.
PVC was estimated in two ways: the proportion of vaccinated among at-risk ILI cases reported by the SGPs during the epidemic period [9, 12] and the proportion of vaccinated among at-risk influenza-confirmed cases swabbed by the SGPs during the epidemic period [9] . The epidemic periods considered are those declared by the Sentinelles Network (http://www.sentiweb.fr/) [21] .
VE was estimated with a logistic regression model stratified by age (two age strata: <65 years with chronic diseases, and !65 years), with the number of vaccinated cases as the response variable, a binomial error structure equal to the total number of cases and the logit of PV as a different offset in each age stratum [7] .
We also evaluated the ability of the SM based on ILI cases to provide real-time VE estimates during the season. In order to compute the estimates retrospectively, we used the PV reported at the end of the previous influenza season [12] .
Estimation of seasonal VE using TND
With the TND, VE is estimated as (1 À odds ratio (OR)) Â 100% [18, 22] . We used multivariate logistic regression with influenza laboratory result as outcome and vaccination status as the main effect to compute the OR of vaccination, while adjusting for the following potential confounding factors: age (coded into eight age bands), time of onset of symptoms, presence of a risk factor for influenza complications other than age (chronic disease, pregnancy or obesity) and gender [23] . We conducted a complete case analysis, excluding patients with missing values for any of the variables included in the model and those recruited outside the virus circulation period as defined by the European Centre for Disease Prevention and Control protocol [24] (Fig. 1) .
VE was estimated for both the general population and the atrisk population, overall and by virus (sub)type or lineage, for all ages or by age group.
Real-time VE estimations were carried out on a weekly basis starting with the first week of the epidemic until the end of the virus circulation period. 
Ethical statement
The protocol was conducted in agreement with the Helsinki declaration. Authorization was obtained from the French Data Protection Agency (CNIL, registration 471393).
Results
Description of 2014e15 and 2015e16 influenza seasons in France
Dynamics of the 2014e15 and 2015e16 influenza seasons in France are reported in Supplementary Fig. A1 .
In season 2014e15, a total of 11 508 ILI cases were described by the SGPs during the 9-week epidemic period (from 12 January to 15 March 2015) ( Supplementary Fig. A1 and Supplementary Table A1 ). Among the 2613 virologic specimens collected along the entire season (ISO (International Organization for Standardization) weeks, 2014w40 to 2015w15), 55.6% (n ¼ 1450) were influenza positive, of which 54.8% (n ¼ 794) were subtyped as A(H3N2).
In season 2015e16, a total of 9945 ILI cases were described during the 11-week epidemic period (from 25 January to 10 April 2016) ( Supplementary Table A1 ). Among the 4031 specimens collected during the season (ISO weeks, 2015w40 to 2015w19), 52.7% (n ¼ 2123) were influenza positive, of which 69.6% (n ¼ 1478) were type B viruses of lineage Victoria.
Study population
Screening method
During the 2014e15 influenza epidemic, 1401 ILI cases and 218 influenza-positive patients belonged to a group at risk (with chronic disease or aged !65 years) and were eligible for inclusion in the SM-VE study. Among these, 533 ILI patients (38.0%) and 86 influenza-positive patients (39.4%) were vaccinated with the seasonal vaccine (Table 1 and Supplementary Table A1 ). During the 2015e16 influenza epidemic, 700 ILI patients and 137 influenzapositive patients belonged to the at-risk groups (with chronic disease or aged !65 years) and were eligible for inclusion in the study. The vaccine coverage was 27.0% (n ¼ 189) in ILI patients and 27.7% (n ¼ 38) in influenza-positive patients ( Table 1 and Supplementary  Table A1 ).
Test-negative design
In season 2014e15, a total of 2397 swabbed patients with informed vaccination status (1413 cases and 984 controls) were eligible for inclusion in the TND-VE study, of whom 8.7% (n ¼ 208) were vaccinated (9.1% of cases (n ¼ 129) and 8% of controls (n ¼ 79)). In season 2015e16, there were 3676 swabbed patients (2084 cases and 1664 controls) with informed vaccination status eligible for the study, of whom 5.1% (n ¼ 187) were vaccinated (4.9% of cases (n ¼ 101) and 5.3% of controls (n ¼ 86)). Characteristics of the participants included are reported in Supplementary Table A2 .
Estimated VE by using SM
In season 2014e15, the overall estimated VE among at-risk groups was 24% (95% confidence interval (CI), 16 to 32) against medically attended ILI and 12% (95% CI, À16 to 33) against any influenza virus infection; in season 2015e16, the overall estimated VE among the population at risk was 53% (95% CI, 44 to 60) in preventing ILI and 47% (95% CI, 23 to 64) against any influenza virus infection ( Table 1) . Additional details on SM-VE estimates by virus type and subtype are reported in Supplementary Table A3 . 
Estimated VE using TND
In season 2014e15, the overall adjusted VE estimates among the general population were À17% (95% CI, À79 to 24) against all influenza viruses and À46% (95% CI, À140 to 11) against influenza A(H3N2) ( Table 2) . Among the population at risk, the overall adjusted VE estimate against all influenza viruses was À38% (95% CI, À119 to 13) ( Table 1 ). In season 2015e16, the overall adjusted VE estimates in the general population were 10% (95% CI, À31 to 39) against all influenza viruses and À22% (95% CI, À85 to 20) against influenza B (Table 2 ). Among the population at risk, the overall adjusted VE point estimate was 18% (95% CI, À33 to 50) ( Table 1 ).
Detailed VE estimates by age subgroups and virus (sub)type and lineage are reported in Supplementary Table A4 .
Estimation of VE in real time
Screening method
In 2014e15, the SM provided real-time VE estimates that were stable and precise after the third week of epidemic; the intermediate VE point estimate was 13% higher than the final one among the overall at-risk group (0e64 years, þ3%; elderly, þ14%). In 2015e16, the real-time VE estimates became stable after the fourth week of epidemic, when the intermediate VE point estimate overestimated the final value by 2% among the overall at-risk group (0e64 years, þ2%; elderly, same value) ( Fig. 2(a) ).
Test-negative design
In 2014e15, overall VE could be estimated starting with the second week of epidemic; compared to the first intermediate estimates, the final overall VE point estimates were 5% higher against all influenza viruses (0e64 years: þ61%; elderly: þ3%) and 51% higher against A(H3N2) viruses ( Fig. 2(b) ). In 2015e16, overall VE intermediate estimates were also available from the second week of the epidemic. Compared to the first intermediate results, final VE point estimates were 23% lower overall against all influenza viruses (0e64 years: À8%; elderly; À37%) and 30% lower against type B viruses ( Fig. 2(b) ).
As can be observed from Fig. 2(b) , the start of real-time TND-VE monitoring varied depending on the season and the type of analysis, as it is subject to the availability of a minimum required sample size.
Discussion
To our knowledge, our study is the first to assess the strengths and weaknesses of the SM and the TND methods in estimating influenza VE from active surveillance data collected by the French surveillance system in primary care. Overall, the results suggest that SM seems more suitable to monitor influenza VE at a national level among the population at risk for severe or complicated influenza illness, providing precise real-time VE estimates at early stages of the influenza epidemic. Given its worldwide popularity, the TND provides useful VE estimates in the general population and is comparable among countries using a similar study design.
Test-negative designdresults, strengths and weaknesses
In 2014e15, in agreement with data reported in other European countries [25e30], our all-ages overall TND-VE estimates in the general population indicated no protection of the vaccine against all influenza viruses (À17% (95% CI, À79 to 24)) and against influenza A(H3N2) (À46% (95% CI, À140 to 11)). This result could reflect the antigenic drift between a part of the circulating A(H3N2) viruses and the A(H3N2) virus strain included in the 2014e15 vaccine [14] . In 2015e16, all-ages VE estimates among the general population indicated no protection of the vaccine against influenza type B (À22% (95% CI, À85 to 20)). We observed moderate protection against A(H1N1)pdm09 viruses (45% (95% CI, 3 to 68)), similar to VE estimates published in the United Kingdom (54.5% (95% CI, À41.6 to 64.5)) and by the I-MOVE Consortium (midseason VE, 44.2% (95% CI, À3.1 to 69.8)) [31, 32] .
A large number of patients were excluded from the 2014e15 TND-VE study because of missing information on the presence of a risk factor for influenza complications (other than age) ( Fig. 1) . However, complementary analyses including all cases and not adjusting for this confounder or using multiple imputation to correct for missing values yielded similar results, with slightly higher VE point estimates compared to the complete case analysis, considering the large CIs (from þ8% to þ18% compared to the complete case analysis). Although this confounding factor is often not significant, it was kept in the models, as suggested in the literature [22] , leading to restricted sample size.
Indeed, the main drawback of the TND is the large sample size required to obtain accurate estimations, which is difficult to reach at a national level [33] . Considering the vaccine coverage in our control group (9.3% in 2014e15 and 5.41% in 2015e16) and the observed VE point estimates, 3341 and 3848 participants would have been required in 2014e15 and 2015e16, respectively (instead of 1428 and 3447), in order to achieve a level of precision of 30%, given the observed positivity rates of 59% in 2014e15 and 56% in 2015e16. Thus, in the absence of a sufficient sample size, our results should be interpreted with caution considering the large 95% CIs, all the more when VE is estimated by subgroups such as elderly or at-risk population when sample size limitations are even stronger, making adjustment on some confounding factors impossible and thus altering the precision and accuracy of VE estimates [34] . Therefore, although the TND method could be more suitable for VE estimation at a European level (I-MOVE Consortium), where large sample sizes can be achieved, it does not always provide precise VE estimates at national level. Moreover, real-time VE through the TND method were highly variable across the season, becoming stable only after the epidemic peak or towards the end of each season.
Screening methoddresults, strengths and weaknesses
In agreement with findings from other countries [28,30e32] , the SM-VE indicated a lower protection of the vaccine in season 2014e15 compared to season 2015e16. Similar to the TND, in season 2014e15, the SM-VE indicated a low overall protection of the vaccine in preventing both ILI and influenza infection among the at-risk population in France (24% (95% CI, 16 to 32) and 12% (95% CI, À16 to 33), respectively).
In season 2015e16, in contrast to the TND-VE results, SM-VE estimates in the elderly population (42% (95% CI, 28 to 54) and 33% (95% CI, À21 to 64)) were slightly lower compared to the group aged 0 to 64 years with a chronic condition (64% (95% CI, 54 to 73) and 54% (95% CI, 26 to 72)). However, SM-VE estimates in the elderly by virus (sub)type or lineage indicate a high level of protection of the vaccine against A(H1N1)pdm09 (68% (95% CI, 7 to 91)), but no protection against B viruses (3% (95% CI, À105 to 54)), which is consistent with TND results in the United Kingdom and Europe (33, 34) . SM-VE estimates by virus (sub)type were obtained from small sample sizes and should be interpreted with caution.
The SM allowed estimating real-time VE for preventing ILI at an early stage of the epidemic period, providing early information on the potential protective effect of the vaccine in the French at-risk population. Given the high number of patients consulting for ILI during the epidemic period, the sample size was easily reached, resulting in narrow confidence intervals and a good level of precision from the first weeks of the epidemic (third, and fourth epidemic week for season 2014e15 and 2015e16, respectively). According to Farrington [7] , 601 participants are required in order to reach a level of precision of results of 15%, given a proportion of vaccinated people among the population of reference (PV) of 50% and an expected VE of 50%.
Using a nonspecific endpoint such as medically attended ILI might bias the results by underestimating the VE in seasons with low influenza activity and high incidence of other respiratory viruses [9, 18, 35, 36] . This bias was reduced by using a very specific ILI definition in France [16] and by including in the analysis only the ILI cases reported during the epidemic period [18] . This ensured a proportion of 70% patients positive for influenza among all ILI patients recruited during each epidemic period. When VE point estimates in preventing ILI are slightly higher than VE point estimates in preventing laboratory-confirmed influenza in the population at risk, the 95% CI are overlapping and the sample size of influenzapositive cases is too small to allow for precise results (218 cases for season 2014e15 and 137 for season 2015e16). Although general practitioners are instructed to systematically recruit ILI cases for swabbing regardless their vaccination status, the vaccine coverage in the group of swabbed ILI patients was slightly higher compared to the overall ILI cases at risk, which partially explains the higher VE against influenza compared to VE against ILI.
The SM relies on the availability of adequate values of the vaccine coverage in the reference group, which are not available in real time in France. However, because vaccine coverage in the population at risk was relatively stable across seasons and the studied epidemics occurred late, the value reported at the end of the previous influenza season was a good approximation of the vaccine coverage for the season under study [2] . Data regarding the vaccine coverage in France allowed us to estimate VE only in the at-risk population. However, robust VE estimates for the at-risk group are more informative than estimates in the general population [35] because this group presents the highest risk for severe complications due to influenza and is of greatest interest for the national health authorities [37] . One limitation of our study was the unavailability of more detailed vaccine coverage statistics, which would have allowed for stratification of VE by more specific risk factors and age groups, as well as adjustment for other potential confounding factors [7] . Additionally, although French vaccine recommendation for at-risk people include pregnancy and obesity, these categories were excluded from the SM study because data on vaccine coverage in the reference population for these groups were not available. This aspect should be taken into account when comparing results yielded by the two methods for the population at risk.
In the absence of a reference standard, interpretation of VE results is an important limitation of all VE studies. Regardless of the method used, a deeper understanding is needed (e.g. previous immunization effects, cross-immunity) in order to take into account all potential biases. Even studies carried out at European level, using data pooled from several countries, struggle to obtain precise results [28, 32] . Moreover, interpretation and comparison of results obtained from different studies should be done carefully and should take into account the outcome measured [38] .
However, assuming all these potential biases [6, 9, 12 ] are constant in time, SM-VE estimates can be compared across seasons, which can help national health authorities in evaluating the impact of each seasonal epidemic in at-risk groups. Disposing of precise VE estimates at an early stage of the epidemic is informative on how the current seasonal influenza vaccine works compared to previous seasons. This is of higher importance than obtaining unbiased but imprecise estimates. From this perspective, compared to the TND, the SM could be more adequate for estimating VE at national level for countries with French-like data. national public health agency in France. All authors report no conflicts of interest relevant to this article.
